Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 May 1;64(5):2676-2687.
doi: 10.1093/rheumatology/keae559.

Soluble urine activated leukocyte cell adhesion molecule is a strong predictor of lupus nephritis

Dalena Chu  1 , Noa Schwartz  2 , Jeanette Ampudia  1 , Joel Guthridge  3 , Judith James  3 , Jill P Buyon  4 , Stephen Connelly  1 , Maple Fung  1 , Cherie T Ng  1 ; Accelerating Medicines Partnership: RA/SLE Network; Andrea Fava  5 , Michelle Petri  5 , Chandra Mohan  6 , Chaim Putterman  2   7   8
Collaborators, Affiliations
Multicenter Study

Soluble urine activated leukocyte cell adhesion molecule is a strong predictor of lupus nephritis

Dalena Chu et al. Rheumatology (Oxford). .

Abstract

Objectives: To evaluate urinary activated leucocyte cell adhesion molecule (ALCAM) and CD6 as predictors of LN progression or disease resolution across a 1-year study.

Methods: Serum and urine samples from biopsy proven LN subjects (n = 122) were prospectively collected over the course of a year at 3- or 6-month intervals (weeks 0, 12, 26 and 52) across multiple study sites and assessed for soluble ALCAM and CD6 levels. Urine creatinine from the same urine sample was used to normalize the levels of urinary ALCAM and urinary CD6. Measured levels of serum and urine ALCAM and CD6 were then analysed against disease metrics cross-sectionally and longitudinally.

Results: Cross-sectional analysis at baseline revealed that urinary ALCAM significantly correlated with urine protein creatinine ratio, renal SLEDAI, and the Physician Global Assessment (PGA), and negatively correlated with serum C3 and C4. Receiver operating characteristic curve analysis demonstrated that urinary ALCAM is a predictor of LN with an area under the curve (AUC) of 0.97, compared with urinary CD6 with an AUC of 0.71. Importantly, the change in urinary ALCAM over a 3-month period distinguished between non-responders and responders at week 52.

Conclusion: Urinary ALCAM is reflective of changes in LN and may be predictive of response status.

Keywords: ALCAM; CD6; lupus nephritis; urine biomarkers.

PubMed Disclaimer

References

    1. Anders HJ, Saxena R, Zhao MH et al. Lupus nephritis. Nat Rev Dis Primers 2020;6:7. - PubMed
    1. Moroni G, Depetri F, Ponticelli C. Lupus nephritis: when and how often to biopsy and what does it mean? J Autoimmun 2016;74:27–40. - PubMed
    1. Kernder A, Richter JG, Fischer-Betz R et al. Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: cross sectional analysis of the LuLa cohort. Lupus 2021;30:431–8. - PMC - PubMed
    1. Chalmers SA, Ayilam Ramachandran R, Garcia SJ et al. The CD6/ALCAM pathway promotes lupus nephritis via T cell-mediated responses. J Clin Invest 2022;132:147334. - PMC - PubMed
    1. Chalmers S, Garcia S, Ampudia J, Ng C, Connelly S, Putterman C, eds. Amelioration of immune complex-mediated glomerulonephritis by CD6 modulation. Atlanta, GA: ACR, 2019.

Publication types

MeSH terms